title: Selective brain region activation by histamine H₃ receptor antagonist/inverse agonist ABT-239 enhances acetylcholine and histamine release and increases c-Fos expression.
abstract: Histamine axons originate solely from the tuberomamillary nucleus (TMN) to innervate almost all brain regions. This feature is consistent with a function for histamine over a host of physiological processes, including regulation of appetite, body temperature, cognitive processes, pain perception and sleep-wake cycle. An important question is whether these diverse physiological roles are served by different histamine neuronal subpopulations. Here we report that systemic administration of the non-imidazole histamine H₃ receptor antagonist 4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile (ABT-239, 3 mg/kg) increased c-Fos expression dose-dependently in rat cortex and nucleus basalis magnocellularis (NBM) but not in the nucleus accumbens (NAcc) nor striatum, and augmented acetylcholine and histamine release from rat prefrontal cortex. To further understand functional histaminergic pathways in the brain, dual-probe microdialysis was used to pharmacologically block H₃ receptors in the TMN. Perfusion of the TMN with ABT-239 (10 μM) increased histamine release from the TMN, NBM, and cortex, but not from the striatum or NAcc. When administered locally, ABT-239 increased histamine release from the NBM, but not from the NAcc. Systemic as well as intra-TMN administration of ABT-239 increased c-Fos expression in the NBM, and cortex, but not in the striatum or NAcc. Thus, as defined by their sensitivity to ABT-239, histaminergic neurons establish distinct pathways according to their terminal projections, and can differentially modulate neurotransmitter release in a brain region-specific manner. This implies independent functions of subsets of histamine neurons according to their terminal projections, with relevant consequences for the development of specific compounds that affect only subsets of histamine neurones, thus increasing target specificity.
authors: Dipartimento di Farmacologia Preclinica e Clinica, Universitá degli Studi di Firenze, Viale G. Pieraccini 6, 50139 Firenze, Italy.
authors: L
authors: L
authors: Munari
authors: G
authors: G
authors: Provensi
authors: M B
authors: MB
authors: Passani
authors: P
authors: P
authors: Blandina
mesh_terms: D000109:Acetylcholine / Q000378:metabolism*; D000818:Animals; D001572:Benzofurans / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D054314:Drug Inverse Agonism; D016762:Genes, fos / Q000187:drug effects; D006632:Histamine / Q000378:metabolism*; D054828:Histamine H3 Antagonists / Q000494:pharmacology*; D008297:Male; D009474:Neurons / Q000378:metabolism; D011759:Pyrrolidines / Q000494:pharmacology*; D051381:Rats
chemical_list: D001572:Benzofurans; D054828:Histamine H3 Antagonists; D011759:Pyrrolidines; D006632:Histamine; C496397:benzonitrile, 4-(2-(2-((2r)-2-methyl-1-pyrrolidinyl)ethyl)-5-benzofuranyl)-; D000109:Acetylcholine